false

Kurt Preugschat

Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team.

• Read: Phase 1 Clinical Trial Designs Explained: BOIN, CRM, BLRM & Modern Adaptive Strategies

  Clinical Trials

  Phase 1 Clinical Trial Designs Explained: BOIN, CRM, BLRM & Modern Adaptive Strategies

  Jun 09, ‘25 | 6 min read

  • 

    Kurt Preugschat

  Discover
• Read: Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

  Clinical Trials

  Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

  Jun 08, ‘25 | 5 min read

  • 

    Kurt Preugschat

  Discover
• Read: Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

  Clinical Trials

  Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

  Jun 06, ‘25 | 5 min read

  • 

    Kurt Preugschat

  Discover
• Read: Case Study: Concurrent Phase 1 Solid Tumor Drug Development Successes

  Clinical Trials

  Case Study: Concurrent Phase 1 Solid Tumor Drug Development Successes

  Feb 24, ‘25 | 4 min read

  • 

  • Anna R.

    Kurt P.

  Discover
• Read: Case Study: A Double Rescue in Advanced Solid Tumor Clinical Trials

  Clinical Trials - Oncology

  Case Study: A Double Rescue in Advanced Solid Tumor Clinical Trials

  Sep 05, ‘24 | 5 min read

  • 

  • Joy T.

    Kurt P.

    Ijeoma O.

  Discover
• Read: Administering Event-Driven Clinical Trials: A Biostatistical Analysis

  Clinical Trials

  Administering Event-Driven Clinical Trials: A Biostatistical Analysis

  Mar 07, ‘24 | 5 min read

  • 

    Kurt Preugschat

  Discover
• Read: Phase I Clinical Trial Designs: Backfill i3+3 (Bi3+3)

  Clinical Trials - Early Phase Research - Oncology

  Phase I Clinical Trial Designs: Backfill i3+3 (Bi3+3)

  Oct 20, ‘23 | 3 min read

  • 

    Kurt Preugschat

  Discover

Loading...

You've reach the end Back to top